Santen eyes uveitis market with top-line sirolimus data
This article was originally published in Scrip
Executive Summary
Japanese eye company Santen has released positive top-line data for the first Phase III trial of its sirolimus-based uveitis treatment.
You may also be interested in...
Keeping Track: So. Much. News.
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Breakthroughs Dominate 2017 Novel Agents; US FDA Approves Rydapt, Alunbrig, Tymlos, Brineura
The latest drug development news and highlights from our FDA Performance Tracker.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.